Molecular Partners AG

SWX:MOLN Stock Report

Market Cap: CHF 112.5m

Molecular Partners Balance Sheet Health

Financial Health criteria checks 5/6

Molecular Partners has a total shareholder equity of CHF68.5M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF87.7M and CHF19.2M respectively.

Key information

0%

Debt to equity ratio

CHF 0

Debt

Interest coverage ration/a
CashCHF 78.77m
EquityCHF 68.45m
Total liabilitiesCHF 19.21m
Total assetsCHF 87.66m

Recent financial health updates

Recent updates

Analysis Article Mar 13

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Sep 10

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Apr 11

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Key Insights Molecular Partners to hold its Annual General Meeting on 17th of April Salary of CHF385.0k is part of CEO...
Analysis Article Jan 09

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article Sep 08

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article Jun 23

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

The latest analyst coverage could presage a bad day for Molecular Partners AG ( VTX:MOLN ), with the analysts making...
Analysis Article Aug 31

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

One thing we could say about the analysts on Molecular Partners AG ( VTX:MOLN ) - they aren't optimistic, having just...
Analysis Article May 09

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Dec 26

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Shareholders in Molecular Partners AG ( VTX:MOLN ) may be thrilled to learn that the analysts have just delivered a...

Financial Position Analysis

Short Term Liabilities: MOLN's short term assets (CHF82.9M) exceed its short term liabilities (CHF8.8M).

Long Term Liabilities: MOLN's short term assets (CHF82.9M) exceed its long term liabilities (CHF10.4M).


Debt to Equity History and Analysis

Debt Level: MOLN is debt free.

Reducing Debt: MOLN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOLN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MOLN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/05 09:18
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecular Partners AG is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurnsH.C. Wainwright & Co.
Richard VosserJ.P. Morgan
Wei ChangLeerink Partners LLC